Latest News
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
ACCESSWIRE - Mon Nov 18, 2:00AM CST
ACCESSWIRE
Mon Nov 18, 2:00AM CST
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
ACCESSWIRE - Wed Oct 9, 11:05AM CDT
ACCESSWIRE
Wed Oct 9, 11:05AM CDT
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live...
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
MarketBeat - Wed Sep 25, 6:15AM CDT
MarketBeat
Wed Sep 25, 6:15AM CDT
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
ACCESSWIRE - Wed Sep 11, 2:00AM CDT
ACCESSWIRE
Wed Sep 11, 2:00AM CDT
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide)...
Bausch Health Responds to Market Rumors
ACCESSWIRE - Wed Jul 24, 7:50AM CDT
ACCESSWIRE
Wed Jul 24, 7:50AM CDT
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorgยฎ today, citing unnamed sources.
Stocks driving the TSX: RBC becomes biggest contributor to Composite returns over last three months
The Globe and Mail - Thu May 23, 10:48AM CDT
The Globe and Mail
Thu May 23, 10:48AM CDT
The biggest points detractor from index returns hasnโt changed since our last update, but the biggest contributor might come as a bit of a surprise
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
ACCESSWIRE - Wed May 15, 3:00AM CDT
ACCESSWIRE
Wed May 15, 3:00AM CDT
LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
ACCESSWIRE - Tue May 14, 11:21AM CDT
ACCESSWIRE
Tue May 14, 11:21AM CDT
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc.
Why Bausch Health Companies Stock Dived by More Than 7% Today
Motley Fool - Thu May 2, 5:43PM CDT
Motley Fool
Thu May 2, 5:43PM CDT
A large red number on the bottom line attracted the wrong kind of investor attention for the company.
This Bausch Health Companies Unusually Active Option Is a No-Brainer
Barchart - Thu Mar 28, 12:00PM CDT
Barchart
Thu Mar 28, 12:00PM CDT
Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical companyโs unusual options activity suggests it might have more gains ahead.
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
ACCESSWIRE - Tue Dec 5, 2023
ACCESSWIRE
Tue Dec 5, 2023
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal...
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
ACCESSWIRE - Fri Nov 10, 2023
ACCESSWIRE
Fri Nov 10, 2023
Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis
CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
ACCESSWIRE - Thu Nov 9, 2023
ACCESSWIRE
Thu Nov 9, 2023
This corrects and replaces the release that was disseminated earlier today
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
ACCESSWIRE - Wed Nov 8, 2023
ACCESSWIRE
Wed Nov 8, 2023
Company Introduces Multimedia Resources to Bring Awareness of SAD
Bausch Health Announces Third-Quarter 2023 Results
ACCESSWIRE - Thu Nov 2, 2023
ACCESSWIRE
Thu Nov 2, 2023
LAVAL, QC / ACCESSWIRE / November 2, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter.
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
ACCESSWIRE - Wed Nov 1, 2023
ACCESSWIRE
Wed Nov 1, 2023
LAVAL, QC / ACCESSWIRE / November 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced that the U.S. District Court for the District of Columbia in the matter of...
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
ACCESSWIRE - Thu Oct 26, 2023
ACCESSWIRE
Thu Oct 26, 2023
First-Ever Television Ad Campaign for APLENZINยฎ (bupropion hydrobromide) Airs in October
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
ACCESSWIRE - Fri Oct 20, 2023
ACCESSWIRE
Fri Oct 20, 2023
First and only FDA-approved fixed-dose, triple-combination topical treatment
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
ACCESSWIRE - Tue Oct 17, 2023
ACCESSWIRE
Tue Oct 17, 2023
Hurdles Led to Almost All Patients Having At Least One Day Delay to Receive Treatment with Xifaxanยฎ
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
ACCESSWIRE - Thu Oct 12, 2023
ACCESSWIRE
Thu Oct 12, 2023
LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S....
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
ACCESSWIRE - Tue Oct 10, 2023
ACCESSWIRE
Tue Oct 10, 2023
LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving...
Salix Pharmaceuticals Partners with Bellamy Young
ACCESSWIRE - Wed Oct 4, 2023
ACCESSWIRE
Wed Oct 4, 2023
Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting Hepatic Encephalopathy
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
ACCESSWIRE - Fri Sep 29, 2023
ACCESSWIRE
Fri Sep 29, 2023
LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its...
BHC FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC
TheNewswire.com - Sun Sep 24, 2023
TheNewswire.com
Sun Sep 24, 2023
WHY:ย NEW YORK, NY - (NewMediaWire) - September 23, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between August 6, 2020 and May 3, 2023, both dates inclusive...
BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit
PR Newswire - Fri Sep 22, 2023
PR Newswire
Fri Sep 22, 2023
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...